Protective Effect and Mechanism of SGLT2 Inhibitor on Heart Failure with Preserved Ejection Fraction
Heart failure is the terminal stage and the main cause of death in the development of cardiovascular disease,with a high prevalence rate,rehospitalization rate and mortality rate,making the prevention and treatment extremely difficult.Among them,heart failure with preserved ejection fraction(HFpEF)is the main type of heart failure,accounting for about 50％of the total number of heart failure,and more than 70％of people over 65 years old.With the emergence of new anti-heart failure drugs,the patients'rehospitalization rate and mortality rate of heart failure with reduced ejection fraction have gradually decreased,but HFpEF still faces a treatment dilemma.It has been reported that sodium-glucose co-transporter 2 inhibitor act independently on the heart,and treat heart failure patients through multiple mechanisms,but the biological mechanisms that provide clinical benefits have not been fully elucidated.
Heart failureHeart failure with preserved ejection fractionSodium-glucose co-transporter 2 inhibitor
NETL
NSTL
万方数据
